Journal of Pain and Symptom Management
Volume 40, Issue 6 , Pages 883-891 , December 2010

Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy

,Accepted 1 April 2010.

References 

  1. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–1515
  2. Yardley DA. Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist. 2009;14:448–455
  3. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–725
  4. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27–46
  5. Kautio A-L, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35:31–39
  6. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98:195–203
  7. Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112:2802–2808
  8. Rao RD, Michalak JC, Sloan JA, et al. North Central Cancer Treatment Group Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–2118
  9. Nikcevich DA, Grothey A, Sloan JA, et al. A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol. 2008;26(May 20 Suppl):abstract 4009
  10. Barton DL, Wos E, Qin R, et al. A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA. J Clin Oncol. 2009;27(15 Suppl):abstract 9531
  11. Folletti A, Durrer A, Buchser E. Neurostimulation technology for the treatment of chronic pain: a focus on spinal cord stimulation. Expert Rev Med Devices. 2007;4:201–214
  12. de Leon-Casasola OA. Spinal cord and peripheral nerve stimulation techniques for neuropathic pain. J Pain Symptom Manage. 2009;38(2 Suppl):S28–S38
  13. Mailis-Gagnon A, Furlan AD, Sandoval JA, Taylor R. Spinal cord stimulation for chronic pain. Cochrane Database Syst Rev. 2004;(3):CD003783
  14. Harke H, Gretenkort P, Ladleif HU, Rahman S. Spinal cord stimulation in sympathetically maintained complex regional pain syndrome type I with severe disability. A prospective clinical study. Eur J Pain. 2005;9:363–373
  15. Harke H, Gretenkort P, Ladleif HU, Koester P, Rahman S. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth Analg. 2002;94:694–700
  16. Wong R, Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy—a case series. Acupunct Med. 2006;24:87–91
  17. Marineo G. Untreatable pain resulting from abdominal cancer: new hope from biophysics?. JOP. 2003;4:1–10
  18. Sabato AF, Marineo G, Gatti A. Calmare therapy. Minerva Anestesiol. 2005;71:479–482
  19. Attal N, Cruccu G, Haanpää M, et al. EFNS Task Force EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169
  20. Bennett MI, Johnson MI, Brown SR, et al. Feasibility study of transcutaneous electrical nerve stimulation (TENS) for cancer bone pain. J Pain. 2010;11:351–359
  21. Agnew WF, McCreery DB. Considerations for safety with chronically implanted nerve electrodes. Epilepsia. 1990;31(Suppl 2):S27–S32
  22. Smith TJ, Staats PJ, Pool G, et al. Randomized clinical trial of comprehensive medical management of refractory cancer pain vs. comprehensive medical management plus intrathecal implantable drug delivery systems. J Clin Oncol. 2002;20:4040–4049
  23. Loprinzi CL, Paice J. Neuropathic pain from chemotherapy in cancer: diagnosis and treatment dilemmas. WHO Cancer Pain Release. 2008;21:6–7
  24. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;15:3662–3673
  25. Ghoname EA, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA. 1999;281:818–823
  26. Robb KA, Bennett MI, Johnson MI, Simpson KJ, Oxberry SG. Transcutaneous electrical nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2008;(3):CD006276
  27. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007;11:901–913
  28. Postma TJ, Aaronson NK, Heimans JJ, et al. EORTC Quality of Life Group The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41:1135–1139

PII: S0885-3924(10)00521-X

doi: 10.1016/j.jpainsymman.2010.03.022

Journal of Pain and Symptom Management
Volume 40, Issue 6 , Pages 883-891 , December 2010

Article Tools

* Image Usage & Resolution